Comparison Between hCG and GnRH Agonist for Ovulation Induction in Patients With High Response to IVF Drugs
Recruitment status was Active, not recruiting
hCG and GnRH agonist can be used to induce final oocyte maturation and ovulation in IVF cycles. These two approaches will be compared in this study in terms of pregnancy rates and embryological data using patients with hyper-response to IVF drugs.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Administration of Human Chorionic Gonadotropin (hCG) Versus Gonadotropin Releasing Hormone (GnRH) Agonist for Ovulation Induction in Hyper-Responder Patients|
- Ongoing pregnancy per embryo transfer
- Biochemical pregnancy per embryo transfer
- Clinical pregnancy per embryo transfer
- Embryological data
|Study Start Date:||November 2003|
|Estimated Study Completion Date:||July 2005|
hCG is commonly used for the substitution of the endogenous LH surge to induce oocyte maturation and ovulation induction in ovarian hyperstimulation protocols for in vitro fertilization (IVF). However, hCG is related to the occurrence of the ovarian hyperstimulation syndrome (OHSS), a potentially life-threatening complication and hyper-responding patients are particularly in high risk. An alternative to exogenous hCG is the administration of a GnRH agonist inducing an endogenous rise in both LH and FSH levels due to the initial flare effect.
Comparisons: Pregnancy rates and embryological data will be compared from hyper-responding patients receiving either GnRH agonist (Arvekap) or hCG (Pregnyl) for ovulatrion induction following a GnRH antagonist treatment cycle.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00415792
|Athens, Greece, 11528|
|Principal Investigator:||Tryfon Lainas, PhD||Eugonia|